Dyne Therapeutics Company Research Report

Company Overview

• Name: Dyne Therapeutics, Inc.

• Mission: To advance innovative, life-transforming therapeutics for people living with genetically driven muscle diseases.

• Founded: No information is available.

• Founders: No information is available.

• Key People:

• John Cox, MBA - President and Chief Executive Officer

• Doug Kerr, M.D., Ph.D., MBA - Chief Medical Officer

• Johanna Friedl-Naderer - Chief Commercial Officer

• Oxana Beskrovnaya, Ph.D. - Chief Scientific Officer

• Ashish Dugar, Ph.D., MBA - Chief Medical Affairs Officer

• Debra Feldman - Chief Regulatory Affairs Officer

• Lucia Celona - Chief Human Resources Officer

• John Najim, MBA - Chief Technical Officer

• Rick Scalzo, MBA - Senior Vice President, Head of Finance & Administration

• Amy Reilly - Senior Vice President, Head of Corporate Communications & Investor Relations

• Daniel Wilson - Senior Vice President, Head of Legal

• Wildon Farwell, M.D., MPH - Dyne Medical Advisor

• Headquarters: 1560 Trapelo Road, Waltham, MA 02451, USA

• Number of Employees: Approximately 140 (as of end of 2023)

• Revenue: No information is available.

• Known For: Developing muscle-targeted therapies using the proprietary FORCE™ platform to address genetically driven muscle diseases.

Products

• FORCE™ Platform:

• High-level Description: A proprietary platform designed to overcome limitations in muscle tissue delivery of therapeutics, aimed at stopping or reversing disease progression in muscle diseases using modern oligonucleotides.

• Key Features:

• Utilizes antigen-binding fragments (Fabs) engineered to target muscle cells.

• Enhanced tissue penetration and increased tolerability.

• Allows for targeted delivery, extended dosing intervals, and reduced immune activation.

Recent Developments

• Recent Developments:

• Presented data at various scientific congresses and published research highlighting the effectiveness of the FORCE™ platform in muscle disease therapeutics.

• Collaborated with CureDuchenne in hosting fundraising events like The Muscle to Keep Life Moving™, raising over $135,000 for mobility assistance funds.

• Partnered with the University of Notre Dame to support patient advocacy programs and hosted internship opportunities.

• New Products/Features:

• DYNE-101: Investigational therapeutic for myotonic dystrophy type 1 (DM1), currently in Phase 1/2 ACHIEVE trial.

• DYNE-251: Investigational therapeutic for Duchenne muscular dystrophy (DMD), targeting exon 51 skipping, currently in Phase 1/2 DELIVER trial.

• DYNE-302: An investigational therapeutic designed to reduce DUX4 expression in facioscapulohumeral muscular dystrophy (FSHD).

Partnerships

• Partnerships:

• Collaboration with academic institutions like University of Notre Dame focusing on patient advocacy.

• Engagements with advocacy groups for disease awareness and community activities, such as Rare Disease Day.

Contact Information

• Email: info@dyne-tx.com

• Phone: 781.786.8230

• Social Media:

• [LinkedIn](www.linkedin.com)

• [Twitter](twitter.com)

• [Facebook](www.facebook.com)

This report provides an overview of Dyne Therapeutics and its focus on developing therapeutics for muscle-targeted diseases leveraging their proprietary FORCE™ platform, with active clinical trials and ongoing community engagement.